U.s. Securities And Exchange Commission

GettyImages/Skarie20

Amneal expands NY site ahead of Impax merger

By Flora Southey

Amneal Pharmaceuticals expects to bring production of some Impax Laboratories’ drugs in-house through a 100,000 sq. ft. expansion at its site in New York state.

inVentiv preps for $100m IPO

inVentiv preps for $100m IPO

By Gareth Macdonald

US CRO inVentiv Health has signaled its intention to go public by filing an S1 with the Securities and Exchange Commission (SEC) last night.

Catalent looks to go public with $100m IPO

Catalent looks to go public with $100m IPO

By Dan Stanton

Catalent has filed an initial public offering (IPO) with the SEC to raise $100m though this could reach upwards of $500m, according to one investment firm.

AMRI to streamline US workforce and mothball R&D lab

AMRI to streamline US workforce and mothball R&D lab

By Gareth Macdonald

Albany Molecular Research (AMRI) says ‘streamlining’ plan will focus on its drug licensing unit not its contract API research, development and manufacturing services division.

How much does the boss earn - CEO pay at CROs

How much does the boss earn - CEO pay at CROs

By Nick Taylor

Outsourcing-Pharma views the wages of CEOs at six major CROs using interactive charts to explore their basic salary, incentives and how much they get paid compared to company revenues.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All